US-based biotechnology company Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma ...

Enrollment underway for patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) Company expects to share preliminary Phase 1 clinical data in the first half of 2 ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Adicet Bio ( (ACET) ) has issued an update.

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

Belzutifan is indicated as monotherapy to treat adult patients with von Hippel-Lindau disease who require therapy for associated localized renal cell carcinoma ... was based on the results of two main ...

The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Kidney Cancer Session II. Dr Mark Ball discussed ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...

AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...